Provectus Biopharmaceuticals, Inc. (PVCT)

Market Cap	50.91M
Revenue (ttm)	723.92K
Net Income (ttm)	-3.03M
Shares Out	420.28M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	107,000
Open	0.121
Previous Close	0.120
Day's Range	0.114 - 0.121
52-Week Range	0.045 - 0.225
Beta	0.59
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About PVCT

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company’s lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis. It is also developing oral formulations for adul...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 4
• Stock Exchange: OTCMKTS
• Ticker Symbol: PVCT

Financial Performance

In 2023, PVCT's revenue was $557,710, a decrease of -43.61% compared to the previous year's $989,042. Losses were -$3.10 million, -12.74% less than in 2022.